Previous 10 | Next 10 |
The following slide deck was published by TScan Therapeutics, Inc. in conjunction with this event. For further details see: Tscan Therapeutics (TCRX) Investor Presentation - Slideshow
WALTHAM, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the accept...
Summary Baker Brothers’ 13F portfolio value increased from $17.40B to $17.63B this quarter. Global Blood Therapeutics, Horizon Therapeutics, and Kymera Therapeutics were increased during the quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, a...
Financing supports management’s focus on clinical execution and advancing its ImmunoBank Initial $30 million tranche extends cash runway into the second quarter of 2024 WALTHAM, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), ...
WALTHAM, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that mana...
TScan Therapeutics press release ( NASDAQ: TCRX ): Q2 GAAP EPS of -$0.63 beats by $0.13 . Revenue of $4.05M (+42.6% Y/Y) beats by $1.05M . For further details see: TScan Therapeutics GAAP EPS of -$0.63 beats by $0.13, revenue of $4.05M beats by $1.05M
Phase 1 umbrella trial for hematologic malignancies open for enrollment Publication in Cell further validates use of foundational technology to identify novel tumor antigens and effective TCRs TSC-200-A2 (HPV) and TSC-204-C7 (MAGE-A1) IND filings anticipated by year-...
WALTHAM, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that David...
TScan screening technology used to identify the targets of expanded T cell clones in the tumors of patients with head and neck cancer responding to neoadjuvant immunotherapy TCR for C*07:02-restricted epitope on MAGE-A1 forms the basis of TScan’s TSC-204-C07 TCR-T therape...
TScan Therapeutics ( NASDAQ: TCRX ) has appointed Dr. Debora Barton, as Chief Medical Officer. Most recently, Dr. Barton was the Chief Medical Officer at Carisma Therapeutics. In May, TScan got FDA nod to start trial of TSC-101 in blood cancer patie...
News, Short Squeeze, Breakout and More Instantly...
TScan Therapeutics Inc. Company Name:
TCRX Stock Symbol:
NYSE Market:
TScan Therapeutics Inc. Website:
2024-07-26 15:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-16 12:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-26 16:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...